[Effect of enape combined with nebilet in hypertension]

Patients with stage II hypertensive disease have been shown to derive apparent benefit from treatment with a combination of the beta-adrenoblocker nebivolol and inhibitor of the angiotensin-converting enzyme enap that was evidenced by improvement in hemodynamics, in echocardiographic characteristics promoting a decline in the activity of the basic enzyme of the tissue formation angiotensin II chimase and an increase in the level of its most important inhibitor alpha-2-macroglobulin.